Trial Profile
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-062; MK-3475-062/KEYNOTE-062
- Sponsors Merck Sharp & Dohme Corp.
- 12 Sep 2023 Last checked against European Clinical Trials Database record.
- 07 Mar 2023 Results of post hoc subgroup analysis (n=187 of patients enrolled in Asia) assessing efficacy ,safety and tolerability of Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma published in the Japanese Journal of Clinical Oncology
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.